Emerald Advisers Raised Its Us Concrete (USCR) Stake; Sophiris Bio Inchares (SPHS) Shorts Increased By 1.27%

May 22, 2018 - By Marie Mckinney

Sophiris Bio, Inc. (NASDAQ:SPHS) Logo

Emerald Advisers Inc increased Us Concrete Inc (USCR) stake by 7.47% reported in 2017Q4 SEC filing. Emerald Advisers Inc acquired 27,146 shares as Us Concrete Inc (USCR)’s stock declined 24.21%. The Emerald Advisers Inc holds 390,338 shares with $32.65M value, up from 363,192 last quarter. Us Concrete Inc now has $966.37 million valuation. The stock increased 0.88% or $0.5 during the last trading session, reaching $57.45. About 91,141 shares traded. U.S. Concrete, Inc. (NASDAQ:USCR) has risen 1.66% since May 22, 2017 and is uptrending. It has underperformed by 9.89% the S&P500.

Sophiris Bio Inchares (NASDAQ:SPHS) had an increase of 1.27% in short interest. SPHS’s SI was 1.73M shares in May as released by FINRA. Its up 1.27% from 1.71 million shares previously. With 123,900 avg volume, 14 days are for Sophiris Bio Inchares (NASDAQ:SPHS)’s short sellers to cover SPHS’s short positions. The SI to Sophiris Bio Inchares’s float is 6.07%. The stock increased 1.38% or $0.05 during the last trading session, reaching $3.55. About 144,955 shares traded. Sophiris Bio, Inc. (NASDAQ:SPHS) has declined 26.06% since May 22, 2017 and is downtrending. It has underperformed by 37.61% the S&P500.

Among 7 analysts covering U.S. Concrete (NASDAQ:USCR), 5 have Buy rating, 0 Sell and 2 Hold. Therefore 71% are positive. U.S. Concrete had 15 analyst reports since November 24, 2015 according to SRatingsIntel. Stifel Nicolaus maintained it with “Buy” rating and $98.0 target in Tuesday, September 26 report. SunTrust maintained the shares of USCR in report on Thursday, October 26 with “Buy” rating. Citigroup initiated the stock with “Neutral” rating in Tuesday, December 15 report. The company was maintained on Tuesday, May 1 by Stifel Nicolaus. The firm has “Buy” rating given on Thursday, April 21 by BB&T Capital. The rating was initiated by Sidoti on Tuesday, November 24 with “Buy”. The company was maintained on Tuesday, August 8 by Stifel Nicolaus. The firm has “Neutral” rating by Sidoti given on Wednesday, April 20. The stock of U.S. Concrete, Inc. (NASDAQ:USCR) has “Buy” rating given on Friday, November 3 by Stifel Nicolaus. The stock has “Buy” rating by DA Davidson on Tuesday, May 1.

Since January 2, 2018, it had 0 insider purchases, and 16 sales for $2.76 million activity. Another trade for 130 shares valued at $7,657 was sold by Sutherland Colin McGill. Shares for $679,693 were sold by SANDBROOK WILLIAM J. BEHRING DAVID ANDREW sold $15,600 worth of stock or 200 shares. 500 shares were sold by Pruitt Ronnie A, worth $36,750. Another trade for 1,000 shares valued at $70,000 was made by Peabody Mark Baker on Thursday, March 1. $20,938 worth of stock was sold by Kohutek Kevin on Tuesday, January 2.

Investors sentiment decreased to 0.98 in Q4 2017. Its down 0.45, from 1.43 in 2017Q3. It dived, as 30 investors sold USCR shares while 67 reduced holdings. 25 funds opened positions while 70 raised stakes. 18.51 million shares or 6.34% more from 17.41 million shares in 2017Q3 were reported. Paloma Prns has invested 0.01% in U.S. Concrete, Inc. (NASDAQ:USCR). Waddell And Reed Fincl Inc invested in 0.05% or 276,846 shares. 29,980 were reported by First Tru Advsrs Lp. Emerald Advisers Pa invested in 390,338 shares. Monarch Prtn Asset Mngmt Limited Liability Com holds 0.23% or 29,280 shares in its portfolio. Teacher Retirement Sys Of Texas has invested 0% in U.S. Concrete, Inc. (NASDAQ:USCR). Agf Invs Incorporated has 116,035 shares for 0.09% of their portfolio. X Mngmt Ltd Com has 1,190 shares for 0% of their portfolio. Principal Financial Group reported 0.03% of its portfolio in U.S. Concrete, Inc. (NASDAQ:USCR). Sei Invests holds 0.03% of its portfolio in U.S. Concrete, Inc. (NASDAQ:USCR) for 116,247 shares. Balyasny Asset Mngmt Llc accumulated 66,494 shares or 0.02% of the stock. State Of Alaska Department Of Revenue has 3,121 shares. 625 were accumulated by Thompson Davis &. Kornitzer Capital Ks stated it has 0.19% of its portfolio in U.S. Concrete, Inc. (NASDAQ:USCR). California State Teachers Retirement System owns 24,985 shares.

Emerald Advisers Inc decreased Clovis Oncology Inc (NASDAQ:CLVS) stake by 73,327 shares to 260,069 valued at $17.69 million in 2017Q4. It also reduced Trex Inc (NYSE:TREX) stake by 135,645 shares and now owns 387,741 shares. Crown Holdings Inc (NYSE:CCK) was reduced too.

More notable recent U.S. Concrete, Inc. (NASDAQ:USCR) news were published by: Seekingalpha.com which released: “US Concrete: Spruce Point Rebuttal” on May 22, 2018, also Schaeffersresearch.com with their article: “Short Seller: This Stock Could Fall 90%” published on May 17, 2018, Seekingalpha.com published: “More on US Concrete Q1 results” on April 30, 2018. More interesting news about U.S. Concrete, Inc. (NASDAQ:USCR) were released by: Seekingalpha.com and their article: “US Concrete: Rainy Days Are Over, 30%-40% Upside For This Firm” published on May 14, 2018 as well as Streetinsider.com‘s news article titled: “US Concrete (USCR) Misses Q1 EPS by 38c, Beats on Revenues” with publication date: April 30, 2018.

Another recent and important Sophiris Bio, Inc. (NASDAQ:SPHS) news was published by Seekingalpha.com which published an article titled: “Premarket analyst action – healthcare” on May 18, 2018.

Sophiris Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company has market cap of $104.01 million. The companyÂ’s primary product candidate is PRX302, which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia , as well as for the treatment of localized low to intermediate risk prostate cancer. It currently has negative earnings. It has a strategic relationship with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of PRX302 and other products for the treatment of the symptoms of BPH, prostate cancer, prostatitis, or other diseases of the prostate; and license agreement with UVIC Industry Partnerships Inc. and The Johns Hopkins University with respect to the use of PRX302 for the development of therapeutics for the symptoms of BPH, prostate cancer, and other non-cancer diseases and conditions of the prostate.

Investors sentiment increased to 2.8 in 2017 Q4. Its up 2.16, from 0.64 in 2017Q3. It improved, as 2 investors sold Sophiris Bio, Inc. shares while 3 reduced holdings. 8 funds opened positions while 6 raised stakes. 1.87 million shares or 14.89% more from 1.63 million shares in 2017Q3 were reported. 1,800 are held by Wells Fargo & Company Mn. Bank Of Montreal Can owns 11,210 shares. Jpmorgan Chase holds 0% or 23,401 shares. Moreover, Vanguard Grp has 0% invested in Sophiris Bio, Inc. (NASDAQ:SPHS) for 784,834 shares. Two Sigma Secs Ltd Liability Corp has invested 0% in Sophiris Bio, Inc. (NASDAQ:SPHS). Blackrock holds 79,047 shares. Citadel Ltd Liability reported 0% in Sophiris Bio, Inc. (NASDAQ:SPHS). Millennium Mngmt reported 199,705 shares or 0% of all its holdings. 19,042 were reported by Geode Ltd Limited Liability Company. Virtu Ltd Liability accumulated 169,790 shares or 0.02% of the stock. Northwestern Mutual Wealth Management Company has 0% invested in Sophiris Bio, Inc. (NASDAQ:SPHS). Moreover, Fincl Bank Of America De has 0% invested in Sophiris Bio, Inc. (NASDAQ:SPHS) for 3,338 shares. Royal Retail Bank Of Canada invested in 0% or 6,485 shares. Palo Alto Invsts Ltd accumulated 0.02% or 247,000 shares. Goldman Sachs Grp has 137,331 shares for 0% of their portfolio.

Among 6 analysts covering Sophiris Bio (NASDAQ:SPHS), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Sophiris Bio had 14 analyst reports since August 30, 2016 according to SRatingsIntel. H.C. Wainwright maintained Sophiris Bio, Inc. (NASDAQ:SPHS) rating on Friday, November 10. H.C. Wainwright has “Buy” rating and $6.0 target. The rating was initiated by Piper Jaffray on Tuesday, August 30 with “Overweight”. The firm has “Buy” rating by H.C. Wainwright given on Wednesday, January 17. Piper Jaffray initiated the shares of SPHS in report on Friday, May 18 with “Buy” rating. The company was maintained on Friday, June 9 by H.C. Wainwright. Maxim Group maintained the shares of SPHS in report on Monday, August 14 with “Buy” rating. The firm has “Buy” rating by H.C. Wainwright given on Thursday, March 22. H.C. Wainwright maintained the stock with “Buy” rating in Tuesday, May 15 report. The firm has “Buy” rating by H.C. Wainwright given on Friday, September 15. The rating was maintained by H.C. Wainwright with “Buy” on Friday, August 11.

Sophiris Bio, Inc. (NASDAQ:SPHS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>